OXGENE ™, a biotechnology company offering integrated detection and manufacturing technologies to the cell and gene industry, announces the introduction of its own self-labeled protein detection (SLIM ™) system.
The modern method allows the identification of antibodies against limb proteins in their native arrangement in mammalian cells, which may catalyze the discovery of new candidates for antibody-based therapies.
In the SLIM demonstration, target membrane proteins and a library of potential binders are expressed in the same mammalian cells. These then proceed through multiple enrichment and purification cycles to obtain a single clone expressing a single-chain variable fragment that can bind to the target antigen.
The SLIM demonstration implements a specific strategy to minimize false positives and ensure that verified binders focus only on physical epitopes. The platform also uses Chinese hamster ovary cells during detection, so binders are far more likely to be compatible with downstream processing.
Detecting antibodies against organ proteins can be challenging because most of the protein sits inside the organs themselves, leaving a smaller epitope on the surface. surface of the organs for antibody binding. Many antibody detection systems rely on the initial clearance and / or sequencing of the target protein.
However, antibodies detected using this approach can often bind to inappropriate parts of the pure protein, rather than extracellular areas, or to linear epitopes within the extracellular environment that are present. happens in his native concord. The SLIM OXGENE mammalian display system is designed to overcome these barriers by detecting antibodies against complex organ proteins in their native arrangement.
In a study published last month in the Journal of Biological Chemistry *, OXGENE scientists used the SLIM platform to detect a panel of novel antibodies against molecular adhesion of oncogenic target epithelial cells, which remained in its native arrangement within the cell membrane. They also demonstrated the potential of these antibodies in killing cancer cells, when used as a target range of CAR-T cells, thus proving the potential of this technology for the detection of new CAR-T or therapeutic treatment.
This work has demonstrated the capability and strengths of the OIMGENE SLIM display platform for antibody detection against limb proteins. Unlike other mammal display systems, the SLIM platform is compatible with libraries of up to a billion types – a ~ 100-fold increase compared to libraries used in traditional mammal display. In addition, the internal compatibility with downstream development increases the chances that antibodies detected by SLIM display will be both physically relevant and suitable for manufacture. ”
Dr. Nathan Robertson, Group Leader on the OXGENE Antibody Detection Team
To learn more about the OIMGENE SLIM demonstration platform, visit www.oxgene.com/antibody.